含固有免疫调节佐剂的HA疫苗保护小鼠免受高致病性禽流感H5N1病毒致死性感染
研究用哺乳动物和细菌表达系统制备高致病性禽流感H5N1病毒A/Alberta/01/2014(AB14)的血凝素(HA)重组蛋白,分别与专有佐剂TriAdj配制,在小鼠中评估候选疫苗效力。肌肉注射两剂TriAdj配制的哺乳动物表达HA(m-HA/TriAdj)对致死性AB14攻击提供完全保护,而其他组无保护;m-HA/TriAdj诱导显著更高的平衡Th1/Th2应答和中和抗体滴度,所有该组小鼠存活且无体重下降和肺部病毒检出。
要点
- m-HA/TriAdj两剂肌肉注射对小鼠致死性AB14 H5N1攻击提供完全保护。
- b-HA/TriAdj、无佐剂b-HA和无佐剂m-HA均未提供保护。
- m-HA/TriAdj诱导显著更高的平衡Th1/Th2应答和中和抗体滴度。
核心结论
- m-HA与TriAdj配制可能对H5N1大流行株跨界感染人类时提供保护。
研究设计与样本
- 用哺乳动物和细菌表达系统制备HPAI H5N1病毒A/Alberta/01/2014(AB14)的重组HA蛋白,纯化后与专有佐剂TriAdj配制,在小鼠中评估候选疫苗效力。
主要发现
- 肌肉注射两剂TriAdj配制的哺乳动物表达HA(m-HA/TriAdj)对致死性AB14攻击提供完全保护。
- 细菌表达HA加TriAdj(b-HA/TriAdj)、无佐剂b-HA和无佐剂m-HA在免疫小鼠中均无保护。
- m-HA/TriAdj诱导显著更高的平衡Th1和Th2应答及中和抗体滴度。
- m-HA/TriAdj组所有小鼠在致死性AB14 H5N1攻击后存活,无体重下降和肺部可检出病毒,表明无疾病或感染迹象。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The highly pathogenic avian influenza (HPAI) H5N1 viruses and their spillover into the human population pose substantial economic and public health threats. Although antiviral drugs have some effect in treating influenza infection, vaccination is still the most effective intervention to prevent possible pandemic outbreaks. We have developed a novel H5 influenza vaccine to improve the world's pandemic preparedness. We produced a hemagglutinin (HA) of HPAI H5N1 virus A/Alberta/01/2014 (AB14) using both mammalian (m) and bacterial (b) expression systems. The purified recombinant proteins were formulated with a proprietary adjuvant (TriAdj) and their efficacy as vaccine candidates was evaluated in mice. Intramuscular delivery of two doses of TriAdj formulated mammalian expressed HA (m-HA/TriAdj) was shown to provide full protection against a lethal challenge of AB14 in mice. In contrast, bacterially expressed HA with TriAdj (b-HA/TriAdj), b-HA without adjuvant, and m-HA without adjuvant resulted in no protection in immunized mice. Furthermore, m-HA/TriAdj elicited significantly higher levels of balanced Th1 and Th2 responses and neutralizing antibody titres. All the mice in the m-HA/TriAdj group survived a lethal AB14 H5N1 challenge and showed no signs of disease or infection as demonstrated by no loss of body weight or detectable virus in the lungs. Our results suggest that m-HA formulated with TriAdj has potential to protect against pandemic H5N1 in the event of its cross over to the human host.
引用
- Lu Y, Landreth S, Liu G, et al. Innate immunemodulator containing adjuvant formulated HA based vaccine protects mice from lethal infection of highly pathogenic avian influenza H5N1 virus. Vaccine. 2020. PMID: 32014270. doi:10.1016/j.vaccine.2020.01.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。